Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
Status: | Completed |
---|---|
Conditions: | Renal Impairment / Chronic Kidney Disease |
Therapuetic Areas: | Nephrology / Urology |
Healthy: | No |
Age Range: | 18 - 79 |
Updated: | 4/21/2016 |
Start Date: | July 2015 |
End Date: | December 2015 |
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
This study will evaluate the effect of various degrees of renal function on the
pharmacokinetics and safety of ALKS 5461.
pharmacokinetics and safety of ALKS 5461.
Inclusion Criteria:
For all subjects:
- Has a body mass index (BMI) of 18.0-40.0 kg/m^2 and a total body weight >50kg
- Agrees to use an approved method of contraception for the duration of the study
- Additional criteria may apply
For subjects with renal impairment:
- Has severe or end stage renal disease, and does not require dialysis
- Has stable renal function for at least 60 days preceding screening
- Additional criteria may apply
Exclusion Criteria:
For all subjects:
- Has any past history or current finding of a clinically significant observed
abnormality, psychiatric or medical condition other than renal impairment
- Has a history of gastrointestinal surgery affecting drug absorption or biliary
elimination, excluding appendectomy or cholecystectomy
- Is pregnant, planning to become pregnant, or lactating
- Has a history of clinically significant allergy or a hypersensitivity to opioids
- Additional criteria my apply
For subjects with renal impairment:
- Has evidence of compromised respiratory function, seizure disorder, or myasthenia
gravis
- Has received a kidney transplant
- Additional criteria may apply
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials